Imatinib mesylate

• Background:

  Imatinib mesylate is a tyrosine kinase inhibitor. It specifically inhibits Bcr-Abl tyrosine kinase, and receptor tyrosine kinases encoded by c-kit and platelet-derived growth factor receptor (PDGFR) oncogenes.

• Description:

  Kinase inhibitor

• Product Name Alternative:

  4-[ (4-Methyl-1-piperazinyl) methyl]-N-[4-methyl-3-[[4- (3-pyridinyl) -2-pyrimidinyl]amino]-phenyl]benzamide methanesulfonate, 4-[ (4-Methylpiperazin-1-yl) methyl]-N- (4-methyl-3-{[4- (pyridin-3-yl) pyrimidin-2-yl]amino}phenyl) benzamide mesylate, CGP 57148, Genfatinib, Glivec, Imatinib methanesulfonate, STI-571

• UNSPSC:

  41116105

• Type:

  Inhibitor

• Source:

  Synthetic

• Field of Research:

  Cell Signaling | Cancer | Apoptosis | Cancer Growth Inhibitors | Tyrosine Kinase Inhibitors

• Purity:

  ≥98% (HPLC)

• Weight:

  0.02

• Format:

  White to beige solid

• Solubility:

  Soluble H2O: soluble10 mg/ml, clear

• Molecular Formula:

  C30H35N7O4S

• Molecular Weight:

  589.7

• Precautions:

  Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.

• References & Citations:

  1. Kantarjian H., et al. (2002). N.E. J. Med. 346(9): 645–652.

• CAS Number:

  152459-95-5